Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230484798> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4230484798 endingPage "950" @default.
- W4230484798 startingPage "944" @default.
- W4230484798 abstract "One of the underlying mechanisms of multidrug resistance (MDR) is cellular over-production of P-glycoprotein (P-gp), which acts as a drug efflux pump. P-gp is encoded by a small group of related genes termed MDR; only MDR1 is known to confer drug resistance. To overcome P-gp-mediated drug resistance, we have developed two anti-MDR1 hammerhead ribozymes driven by the β-actin promoter. Upon transduction of the ribozymes into MDR cells, vincristine resistance was decreased. These two ribozymes were constructed, which showed different cleavage activities. In this study, to determine suitable target sites for the anti-MDR1 ribozyme, the exon 1b–intron 1 boundary, the translation-initiation site, the intron 1–exon 2 boundary and the exon 2–intron 2 boundary, codons 179 and 196 of the MDR1 gene were selected as candidates. To improve the ribozyme activity, a retroviral vector containing RNA polymerase III promoter was used. Stable retrovirus producer cells were generated by transfecting the retroviral vector plasmids carrying the ribozyme into the packaging cell line. Retroviral vector transduction of human leukemia cell lines expressing MDR1 was accomplished by co-culturing these with virus producer cells. Stably transduced cells were selected by G418 and pooled to determine the efficacy of each ribozyme. These ribozyme-transduced cells became vincristine-sensitive concomitant with the decreases in MDR1 expression, P-gp amount and drug efflux pump function. Among the ribozymes tested, the anti-MDR1 ribozyme against the translation-initiation site exhibited the strongest efficacy. This retrovirus-mediated transfer of anti-MDR1 ribozyme may be applicable to the treatment of MDR cells as a specific means to reverse resistance. Int. J. Cancer81:944–950, 1999. © 1999 Wiley-Liss, Inc." @default.
- W4230484798 created "2022-05-11" @default.
- W4230484798 creator A5007613905 @default.
- W4230484798 creator A5036327728 @default.
- W4230484798 creator A5057442335 @default.
- W4230484798 creator A5087280047 @default.
- W4230484798 creator A5087939992 @default.
- W4230484798 date "1999-06-11" @default.
- W4230484798 modified "2023-09-26" @default.
- W4230484798 title "Retrovirus‐mediated transfer of anti‐MRD1 hammerhead ribozymes into multidrug‐resistant human leukemia cells: Screening for effective target sites" @default.
- W4230484798 doi "https://doi.org/10.1002/(sici)1097-0215(19990611)81:6<944::aid-ijc17>3.3.co;2-p" @default.
- W4230484798 hasPublicationYear "1999" @default.
- W4230484798 type Work @default.
- W4230484798 citedByCount "0" @default.
- W4230484798 crossrefType "journal-article" @default.
- W4230484798 hasAuthorship W4230484798A5007613905 @default.
- W4230484798 hasAuthorship W4230484798A5036327728 @default.
- W4230484798 hasAuthorship W4230484798A5057442335 @default.
- W4230484798 hasAuthorship W4230484798A5087280047 @default.
- W4230484798 hasAuthorship W4230484798A5087939992 @default.
- W4230484798 hasConcept C104317684 @default.
- W4230484798 hasConcept C153911025 @default.
- W4230484798 hasConcept C159047783 @default.
- W4230484798 hasConcept C2522874641 @default.
- W4230484798 hasConcept C2778431562 @default.
- W4230484798 hasConcept C2779562191 @default.
- W4230484798 hasConcept C30951146 @default.
- W4230484798 hasConcept C32470452 @default.
- W4230484798 hasConcept C40767141 @default.
- W4230484798 hasConcept C54009773 @default.
- W4230484798 hasConcept C54355233 @default.
- W4230484798 hasConcept C66144319 @default.
- W4230484798 hasConcept C67705224 @default.
- W4230484798 hasConcept C76346623 @default.
- W4230484798 hasConcept C86803240 @default.
- W4230484798 hasConcept C94671646 @default.
- W4230484798 hasConceptScore W4230484798C104317684 @default.
- W4230484798 hasConceptScore W4230484798C153911025 @default.
- W4230484798 hasConceptScore W4230484798C159047783 @default.
- W4230484798 hasConceptScore W4230484798C2522874641 @default.
- W4230484798 hasConceptScore W4230484798C2778431562 @default.
- W4230484798 hasConceptScore W4230484798C2779562191 @default.
- W4230484798 hasConceptScore W4230484798C30951146 @default.
- W4230484798 hasConceptScore W4230484798C32470452 @default.
- W4230484798 hasConceptScore W4230484798C40767141 @default.
- W4230484798 hasConceptScore W4230484798C54009773 @default.
- W4230484798 hasConceptScore W4230484798C54355233 @default.
- W4230484798 hasConceptScore W4230484798C66144319 @default.
- W4230484798 hasConceptScore W4230484798C67705224 @default.
- W4230484798 hasConceptScore W4230484798C76346623 @default.
- W4230484798 hasConceptScore W4230484798C86803240 @default.
- W4230484798 hasConceptScore W4230484798C94671646 @default.
- W4230484798 hasIssue "6" @default.
- W4230484798 hasLocation W42304847981 @default.
- W4230484798 hasOpenAccess W4230484798 @default.
- W4230484798 hasPrimaryLocation W42304847981 @default.
- W4230484798 hasRelatedWork W1527255489 @default.
- W4230484798 hasRelatedWork W1965110748 @default.
- W4230484798 hasRelatedWork W1977325134 @default.
- W4230484798 hasRelatedWork W2090698701 @default.
- W4230484798 hasRelatedWork W2097281192 @default.
- W4230484798 hasRelatedWork W2107378132 @default.
- W4230484798 hasRelatedWork W2385826495 @default.
- W4230484798 hasRelatedWork W3192368952 @default.
- W4230484798 hasRelatedWork W4230484798 @default.
- W4230484798 hasRelatedWork W2492191741 @default.
- W4230484798 hasVolume "81" @default.
- W4230484798 isParatext "false" @default.
- W4230484798 isRetracted "false" @default.
- W4230484798 workType "article" @default.